Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) had its target price hoisted by Leerink Swann from $136.00 to $170.00 in a research note issued to investors on Friday morning. They currently have an outperform rating on the biopharmaceutical company’s stock.

Several other equities research analysts also recently weighed in on the company. Oppenheimer Holdings, Inc. raised Alexion Pharmaceuticals from a market perform rating to an outperform rating and set a $175.00 price target for the company in a report on Friday. Morgan Stanley reaffirmed an overweight rating and set a $153.00 price target (up from $141.00) on shares of Alexion Pharmaceuticals in a report on Friday. BidaskClub raised Alexion Pharmaceuticals from a hold rating to a buy rating in a report on Tuesday, July 25th. TheStreet raised Alexion Pharmaceuticals from a c rating to a b- rating in a report on Friday, July 14th. Finally, SunTrust Banks, Inc. reaffirmed a buy rating and set a $165.00 price target on shares of Alexion Pharmaceuticals in a report on Friday, July 14th. Six investment analysts have rated the stock with a hold rating, twenty have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of Buy and an average price target of $156.85.

Alexion Pharmaceuticals (NASDAQ ALXN) opened at 137.34 on Friday. Alexion Pharmaceuticals has a 12-month low of $96.18 and a 12-month high of $145.41. The stock has a market capitalization of $30.65 billion, a price-to-earnings ratio of 59.56 and a beta of 1.38. The stock’s 50 day moving average is $124.34 and its 200 day moving average is $122.55.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The firm had revenue of $912 million during the quarter, compared to the consensus estimate of $846.15 million. During the same period last year, the company earned $1.13 earnings per share. The company’s revenue for the quarter was up 21.1% on a year-over-year basis. Equities research analysts forecast that Alexion Pharmaceuticals will post $5.41 EPS for the current fiscal year.

WARNING: This report was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/alexion-pharmaceuticals-inc-alxn-pt-raised-to-170-00/1465115.html.

In related news, Director Bros. Advisors Lp Baker acquired 1,348,955 shares of the company’s stock in a transaction that occurred on Wednesday, June 14th. The stock was purchased at an average price of $116.32 per share, for a total transaction of $156,910,445.60. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Ludwig Hantson acquired 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 14th. The shares were bought at an average price of $116.72 per share, with a total value of $1,167,200.00. Following the transaction, the chief executive officer now owns 38,725 shares in the company, valued at approximately $4,519,982. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 2,019,734 shares of company stock valued at $235,606,846. 4.35% of the stock is currently owned by company insiders.

Hedge funds have recently bought and sold shares of the stock. BlackRock Inc. boosted its stake in Alexion Pharmaceuticals by 2,689.8% in the first quarter. BlackRock Inc. now owns 18,628,080 shares of the biopharmaceutical company’s stock valued at $2,258,467,000 after buying an additional 17,960,356 shares during the period. Jennison Associates LLC boosted its stake in Alexion Pharmaceuticals by 15.8% in the first quarter. Jennison Associates LLC now owns 9,622,914 shares of the biopharmaceutical company’s stock valued at $1,166,682,000 after buying an additional 1,309,529 shares during the period. Bank of Montreal Can boosted its stake in Alexion Pharmaceuticals by 628.8% in the second quarter. Bank of Montreal Can now owns 1,423,318 shares of the biopharmaceutical company’s stock valued at $173,174,000 after buying an additional 1,228,025 shares during the period. Bessemer Group Inc. boosted its stake in Alexion Pharmaceuticals by 1,949,640.5% in the second quarter. Bessemer Group Inc. now owns 721,404 shares of the biopharmaceutical company’s stock valued at $87,772,000 after buying an additional 721,367 shares during the period. Finally, State Street Corp boosted its stake in Alexion Pharmaceuticals by 6.8% in the first quarter. State Street Corp now owns 11,298,685 shares of the biopharmaceutical company’s stock valued at $1,369,846,000 after buying an additional 718,756 shares during the period. Institutional investors own 94.37% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.